Mild Cognitive Impairment that Does Not Progress to Dementia: A Population-Based Study
- PMID: 30444944
- PMCID: PMC6367026
- DOI: 10.1111/jgs.15642
Mild Cognitive Impairment that Does Not Progress to Dementia: A Population-Based Study
Abstract
Background/objective: In population studies, most individuals with mild cognitive impairment (MCI) do not progress to dementia in the near term, but rather remain stable MCI or revert to normal cognition. Here, we characterized MCI subgroups with different outcomes over 5 years.
Setting/participants: A population-based cohort (N=1603).
Measurements: Clinical Dementia Rating (CDR); self-reported medical conditions, subjective cognitive concerns, self-rated health, depressive symptoms, blood pressure, medications, blood pressure, APOE genotype, cognitive domain composite scores.
Design: We compared 3 MCI subgroups who progressed to dementia (n=86), stabilized at MCI (n=384), or reverted to normal (n=252), to those who remained consistently normal (n=881), defining MCI as CDR = 0.5 and dementia as CDR≥1. Using multinomial logistic regression models adjusted for demographics, we examined the associations of each group with selected baseline characteristics.
Results: With the normal group for reference, worse subjective cognitive concerns, functional impairments, self-rated health, and depressive symptoms were associated with being in any MCI group. Taking more prescription medications was associated with being in the stable MCI and reverter groups; diabetes and low diastolic blood pressure were associated with stable MCI. The APOE4 genotype was associated with stable and progressive MCI; stroke was associated with progressive MCI. All MCI subgroups were likely to have lower mean composite scores in all cognitive domains and more operationally defined impairments in attention, language, and executive function; reverters were more likely to lack memory and visuospatial impairments.
Conclusions: MCI subgroups with different 5-year outcomes had some distinct characteristics suggesting different underlying causes. The progressors, unlike the reverters, had a profile broadly typical of Alzheimer's disease; the stable MCIs had other, including vascular, morbidity. These data shed light on the heterogeneity of MCI in the population. J Am Geriatr Soc 67:232-238, 2019.
Keywords: aging; cognition; epidemiology.
© 2018, Copyright the Author Journal compilation © 2018, The American Geriatrics Society.
Conflict of interest statement
CONFLICTS OF INTEREST. Dr. Ganguli served on the “AD Patient Journey Working Group” for Biogen, Inc., in 2016 and 2017. All other authors have no potential conflicts to disclose.
Figures
Similar articles
-
Outcomes of mild cognitive impairment by definition: a population study.Arch Neurol. 2011 Jun;68(6):761-7. doi: 10.1001/archneurol.2011.101. Arch Neurol. 2011. PMID: 21670400 Free PMC article.
-
Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition.Dement Geriatr Cogn Disord. 2017;43(3-4):204-214. doi: 10.1159/000456070. Epub 2017 Mar 17. Dement Geriatr Cogn Disord. 2017. PMID: 28301848 Free PMC article.
-
Association of prior stroke with cognitive function and cognitive impairment: a population-based study.Arch Neurol. 2009 May;66(5):614-9. doi: 10.1001/archneurol.2009.30. Arch Neurol. 2009. PMID: 19433661 Free PMC article.
-
Does mild cognitive impairment always lead to dementia? A review.J Neurol Sci. 2016 Oct 15;369:57-62. doi: 10.1016/j.jns.2016.07.055. Epub 2016 Jul 26. J Neurol Sci. 2016. PMID: 27653867 Review.
-
Functional cognitive disorder: dementia's blind spot.Brain. 2020 Oct 1;143(10):2895-2903. doi: 10.1093/brain/awaa224. Brain. 2020. PMID: 32791521 Free PMC article. Review.
Cited by
-
Neuropsychological Assessment for Early Detection and Diagnosis of Dementia: Current Knowledge and New Insights.J Clin Med. 2024 Jun 12;13(12):3442. doi: 10.3390/jcm13123442. J Clin Med. 2024. PMID: 38929971 Free PMC article. Review.
-
EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer's disease.PLoS One. 2024 Aug 8;19(8):e0308137. doi: 10.1371/journal.pone.0308137. eCollection 2024. PLoS One. 2024. PMID: 39116138 Free PMC article.
-
Biomarkers for Alzheimer's Disease in the Current State: A Narrative Review.Int J Mol Sci. 2022 Apr 29;23(9):4962. doi: 10.3390/ijms23094962. Int J Mol Sci. 2022. PMID: 35563350 Free PMC article. Review.
-
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.J Prev Alzheimers Dis. 2022;9(3):507-522. doi: 10.14283/jpad.2022.41. J Prev Alzheimers Dis. 2022. PMID: 35841252 Free PMC article. Review.
-
Predictors of Dementia in the Oldest Old: A Novel Machine Learning Approach.Alzheimer Dis Assoc Disord. 2020 Oct-Dec;34(4):325-332. doi: 10.1097/WAD.0000000000000400. Alzheimer Dis Assoc Disord. 2020. PMID: 32701513 Free PMC article.
References
-
- Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262–1270. - PubMed
-
- Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364:2227–2234. - PubMed
-
- Ganguli M The unbearable lightness of MCI. Int Psychogeriatr. 2014;26:353–359. - PubMed
-
- Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594–1599. - PubMed
-
- Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115–121. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous